Trump Administration, Merck KGaA Forge Agreement to Slash IVF Medication Costs Through Trade Partnership
The Trump administration has secured a significant agreement with German pharmaceutical giant Merck KGaA to dramatically reduce costs for in-vitro fertilization medications. According to reports, the deal includes an 84% discount on key fertility drugs and establishes new pathways for expanded insurance coverage. The arrangement reportedly provides tariff protections for the company in exchange for price reductions and U.S. manufacturing investments.
Breaking: IVF Drug Price Reduction Agreement Reached
President Donald Trump and German pharmaceutical company Merck KGaA have announced a groundbreaking agreement that sources indicate will substantially lower costs for medications essential to in-vitro fertilization treatments. The arrangement, revealed during an Oval Office event, reportedly connects drug price reductions with protections from potential future tariffs.
